FDA's Quality Management System Regulation Takes Effect for Device Manufacturers

The FDA's Quality Management System Regulation took effect on February 2, 2026, replacing the Quality System Regulation that US device manufacturers have operated under since 1996. The new rule amends the device current good manufacturing practice requirements of 21 CFR Part 820 by incorporating the international standard ISO 13485:2016, per the agency's own device program pages.

What changed on February 2?

The QMSR harmonizes the FDA's CGMP framework with the one used by other regulatory authorities, per the agency's program page. Two operational changes took effect the same day: the FDA stopped using the Quality System Inspection Technique (QSIT) for device inspections and began using the inspection process described in Compliance Program 7382.850, and the agency retired two legacy inspection documents (7382.845 and 7383.001), per the FDA's QMSR frequently asked questions page.

The rule was finalized in 2024 after a long comment process, giving manufacturers close to two years to close gaps between the old part 820 text and ISO 13485:2016 clauses. For established device makers already certified to ISO 13485, the burden is largely mapping and documentation; for smaller shops built on the legacy US text, the transition touches design controls, supplier controls and record-keeping.

Does an ISO 13485 certificate now prove compliance?

No. The regulation incorporates ISO 13485:2016 by reference, but the FDA has been explicit that the agency keeps its own requirements layered on top of the standard. The revised part 820 is titled the Quality Management System Regulation, effective February 2, 2026, and it gives the FDA authority to inspect areas such as management review, quality audits and supplier audit reports, per the agency's FAQ page.

That inspection authority is the practical teeth of the change. A certificate from an accredited certification body is evidence a quality system exists, but it is not the legal standard; the FDA's own inspection outcomes under Compliance Program 7382.850 are. Manufacturers that treated the effective date as a paperwork milestone face the difference in their next inspection, since the QMSR program page states the agency began utilizing the updated inspection process on February 2, 2026.

How does the QMSR interact with clearance pathways?

The QMSR sits in the quality-system layer of device regulation, separate from the premarket pathways that get a device on the market. For context, the route a device takes depends on its classification and predicate history, and the general sequence runs:

1. Determine the device's classification and applicable controls.
2. For a device with a lawful predicate, submit a 510(k) premarket notification before marketing.
3. For a novel low-to-moderate-risk device without a predicate, request De Novo classification.
4. For high-risk class III devices, proceed through premarket approval.
5. Maintain QMSR compliance across the product's life, verified by FDA inspection.

The February 2026 change did not alter which pathway a device follows or its review timeline; it changed what a compliant manufacturing operation looks like once the device is cleared or approved. IVD manufacturers are affected alongside therapeutic-device makers, since the quality-system rule reaches all regulated device categories. The agency's pages describe the effective-date mechanics; company-specific remediation status is not yet disclosed by most manufacturers.